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Objectives: Percutaneous intervention for coronary revascularization is associated with an increased risk of
repeat revascularization, especially in patients with diabetes mellitus. In this study we sought to examine the effect
of previous percutaneous intervention on the rate of adverse perioperative outcome and intermediate-term
survival in patients undergoing coronary artery bypass surgery.
Methods: Between January 1, 2001, and December 31, 2006, 1758 consecutive patients with diabetes mellitus
who underwent first-time isolated coronary artery bypass surgery were identified. Survival and major perioper-
ative complications for 1537 patients who did not have prior percutaneous intervention (group 1) were compared
with those in 221 patients with prior percutaneous intervention (group 2) after adjusting for baseline risk factors.
Vital status was determined by using the National Death Index and Social Security Death Index. Age-adjusted
survival at 2 years’ follow-up was calculated with the Cox singular proportional hazards model.
Results: At baseline, group 2 patients had higher incidences of hypercholesterolemia and myocardial infarction.
Compared with group 1 patient, group 2 patients had significantly higher operative mortality (adjusted odds ratio,
4.05; 95% confidence interval, 1.41–11.63), perioperative major adverse cardiac events (adjusted odds ratio,
2.72; 95% confidence interval, 1.08–6.85), and atrial fibrillation (adjusted odds ratio, 1.97; 95% confidence
interval, 1.29–3.01). Group 2 patients had worse age-adjusted survival at 2 years’ follow-up (93.4% vs
87.4%, P< .017).
Conclusions: Patients with diabetes mellitus and a history of percutaneous coronary stenting before coronary ar-
tery bypass surgery were found to have an increased risk of operative death, increased perioperative complica-
tions, and decreased age-adjusted survival at 2 years’ follow-up.Earn CME credits at
http://cme.ctsnetjournals.org
See related editorial on page 276.
Multiple clinical trials and registries that compared the
long-term outcome of coronary artery bypass grafting
(CABG) and percutaneous coronary interventions (PCIs)
have observed that patients initially treated with PCI have
significantly higher rates of repeat revascularization proce-
dures.1-7 The circumstances are even more precarious for
diabetic patients because these patients have higher rates
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PCI, and necessity for subsequent revascularization than
nondiabetic patients.8,9 It is estimated that 13% to 26% of
patients who initially underwent PCI will still undergo
surgical revascularization within 10 years.10 In 2002 alone,
PCI was performed in 652,000 patients, meaning that poten-
tially between 65,000 and 170,000 of these patients might
require CABG in the near future.11
Several recent studies have reported that a history of PCI
before CABG is an independent predictor of in-hospital
mortality and major adverse cardiac events (MACEs). In
a cohort of patients with diabetes mellitus and triple-vessel
disease undergoing elective CABG, previous PCI was
associated with nearly a 3-fold increased risk of in-hospital
death and MACEs.12 Given the frequent use of stents and
the common need for subsequent surgical revascularization,
these findings might have significant implications for an
increasing group of patients. However, conclusions frompre-
vious investigations have generally been limited to short-
term follow-up; intermediate-term and long-term outcomes
after surgical intervention in such patients remain unclear.
The purpose of this study is to compare perioperative
outcome and intermediate-term survival of patients withrgery c August 2009




CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
EF ¼ ejection fraction
MACE ¼ major adverse cardiac event
MI ¼ myocardial infarction
OE ¼ observed/expected
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
STS ¼ Society of Thoracic Surgeons
diabetes mellitus who have a history of PCI before CABG
with those in patients undergoing CABG without a history
of PCI and similar Society of Thoracic Surgeons (STS)–
predicted risk of morbidity and mortality. In addition, we
assessed whether intermediate-term survival was associated
with the number of diseased vessels, left ejection fraction
(EF), the number of stents, or the indication for CABG for
patients with a history of PCI.
MATERIALS AND METHODS
Patients and Setting
The cohort for this study was composed of consecutive patients given
diagnoses of a history of diabetes mellitus who underwent first-time isolated
CABGat a single tertiary-care center between January 1, 2001, andDecember
31, 2006. Subjects were derived from a computerized database combining
elements of the STS National Adult Cardiac Surgery Database (www.sts.org)
and internal outcomes data collected for outcomes management. The STS da-
tabase is the largest cardiac surgical database in the world and is comprised of
information collected prospectively by independent monitors based on pre-
specified and standardized definitions regarding preoperative clinical charac-
teristics, intraoperative variables, and perioperative complications.
This study was reviewed and approved by the Institutional Review
Board of Inova Fairfax Hospital.
Patientswere identified as having diabetes if they had a history of diabetes,
regardless of the method of treatment. Patients with emergency or salvage op-
erative status (n¼ 105), prior CABG (n¼ 83), or myocardial infarction (MI)
within 24 hours of CABG (n ¼ 77) were excluded from analysis. Patients
were identifiedashavingahistoryofPCI if theypreviouslyhadapercutaneous
procedure to unblock a narrowed coronary artery. We included only patients
whohadPCIwith stents; patientswith isolatedpercutaneous transluminal cor-
onary angioplasty, unsuccessful percutaneous transluminal coronary angio-
plasty, or isolated atherectomy were excluded from analysis (n¼ 58).
Vital status was determined from the National Death Index and cross-ref-
erenced with the Social Security Death Index. The National Death Index is
a database of death record information compiled from the 50 states, the
District of Columbia, Puerto Rico, and the US Virgin Islands. The Social
Security Death Index is slightly less sensitive but more specific than the
National Death Index. Follow-up for mortality data was right censored on
January 15, 2008, and there was 100% follow-up.
Clinical Definitions
MACEs were defined as a composite end point of operative death, peri-
operative MI, postoperative intra-aortic balloon pumping, or postoperative
cardiogenic shock. A perioperativeMIwithin 24 hours was diagnosed based
on the following criteria: creatine kinase MB value of greater than 5 times
normal or newQwaves present in 2 ormore contiguous electrocardiographicThe Journal of Thoracic and Cleads. A perioperative MI 24 hours after the operation was diagnosed based
on either evolutionary ST-segment elevations, development of newQ-waves
in 2 or more contiguous leads, new left bundle branch block, or increases in
creatine kinase MB value of greater than 3 times normal.
Operative mortality included all deaths occurring during the hospitaliza-
tion in which the operation was performed, even if after 30 days, and
included those deaths occurring after discharge from the hospital but within
30 days of the procedure unless the cause of death was clearly unrelated to
the operation. Death from any cause was defined as any death during follow-
up. Death from cardiac causes was defined as death from any cardiac cause
(eg, lethal arrhythmia, MI, or circulatory failure).
The STS-predicted risk ofmajormorbidity/mortality is the estimated prob-
ability of a patient experiencing either operativemortality or one of the follow-
ing 5 major perioperative complications: any reoperation, mediastinitis (deep
sternal infection requiring operative intervention), renal failure (acute orwors-
ening renal failure resulting in the increase of serum creatinine to>2.0mg/dL,
an increase of twice the baseline creatinine value, or new dialysis require-
ment), prolongedventilation (pulmonaryventilation>24hours), or permanent
stroke (any neurologic deficit of abrupt onset not resolved within 24 hours).
Perioperative Management
Glucose control. All patients were initiated on the Portland Continu-
ous Intravenous Insulin Protocol on the morning of surgical intervention,
and this was continued until 72 hours postoperatively. Continuous insulin
infusions were titrated to a serum glucose goal of less than 150 mg/dL by
using a standardized protocol.
Myocardial preservation. All patients were managed with inter-
mittent cold blood cardioplegic solution. The method of delivery was retro-
grade and antegrade, and reperfusion of the myocardium was accomplished
with metabolically enhanced warm blood cardioplegic solution.
Statistical Analysis
Continuous data are presented as themean standarddeviation.Categor-
ical data are presented as the frequency and percentage. Between-group
hypothesis tests were accomplished either by using the Student’s t test, the
c2 test, or unconditional logistic regression, where appropriate. Adjustment
for potential confounding variables during logistic regression modeling was
accomplished by using the individual patient-calculatedmodeled probability
of mortality.13 Multivariate unconditional logistic regression modeling was
performed to assess the relationship between operative mortality and 2-year
mortality versus treatment group after adjustment for the potential confound-
ing effects of preoperative clinical and demographic characteristics. Coxpro-
portional hazard models were used to model the effect of select clinical
parameters on 2-year survival, with statistical significance assessed by using
the log-rank test. A further Cox model was used to adjust for the statistically
significant age difference between the CABG and CABG plus PCI groups to
estimate the effect of patient group on 2-year survival.
Observed/expected (OE) ratios of major perioperative complications
(reoperation for bleeding, mediastinitis, renal failure, prolonged ventilation,
permanent stroke, and operative morality) were calculated by dividing the
observed number of events per stratum by the expected number of events.
Expected numbers of events were derived from the summed stratum-spe-
cific probabilities of major perioperative complications based on preopera-
tive clinical characteristics and comorbidities. Expected numbers of cases
per strata were calculated by summing the modeled probabilities of achiev-
ing the target event. P values were 2-tailed, with all analyses performed with




A total of 1758 patients with diabetes mellitus who under-
went CABG and met the inclusion criteria were identifiedardiovascular Surgery c Volume 138, Number 2 317
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DFIGURE 1. Participants. CABG, Coronary artery bypass grafting; Hx, history; PCI, percutaneous coronary intervention.in the database (Figure 1). One thousand five hundred thirty-
seven patients underwent CABG surgery without prior PCI,
and 221 patients were identified as having a history of PCI
with stenting before CABG. Of the 221 patients with prior
PCI, 103 (46.6%) patients had 1 stent and 118 (53.4%) pa-
tients hadmultiple stents placed before surgical intervention.
Table 1 summarizes the perioperative characteristics of
the patients. The average STS-modeled predicted risk of
mortality or morbidity for patients undergoing CABG plus
PCI was similar to that seen in patients undergoing CABG
only (2.2%  2.2% and 1.9%  2.2%, respectively;
P< .113). In both groups the majority of patients were
men older than 60 years; however, patients undergoing
CABG plus PCI were younger than patients undergoing
CABG only (60.1 vs 63.3 years, P<.0001). Patients under-
going CABG plus PCI more frequently had a history of
acute MI and hypercholesterolemia compared with patients
undergoing CABG only. Although there was a difference in
the incidence of history of acute MI, the average EF in both
groups was similar. The distribution of diseased coronary
vessels was significantly different; more patients in the
CABG-only group had triple-vessel disease (85.0% vs
73.8%, P< .001) and left main disease.
Patients undergoing CABG plus PCI were more often
treated with insulin (30.3% vs 23.6%) and less often treated
with oral hypoglycemic medication (57.5% vs 58.0%) or
diet control (12.2% vs 18.3%); however, these differences
in treatments were not statistically significant (P< .089).
Reflecting the higher incidence of MI and hypercholester-
olemia, significantly more patients undergoing CABG plus
PCI were treated with aspirin (67.6% vs 60.7%, P <
.039), b-blockers (81.3% vs 74.4%, P< .021), and statins
(32.8% vs 27.4%, P< .001).
In the CABG plus PCI group, the mean time elapsed
between the last PCI and CABG was 13.7  24 months.
In-stent restenosis was documented in 116 (52.5%) patients
by means of coronary angiographic analysis before CABG.
The indication for CABG after PCI was determined if318 The Journal of Thoracic and Cardiovascular Surwhether target vessel failure or progression of disease in
the other vessels necessitated surgical revascularization.
By using these criteria, there were 4 main indications for
CABG: progression of de novo stenosis (135 [61.1%]
patients), restenosis of previous stents (44 [19.9%] patients),
combination of progression of disease and restenosis
(37 [16.7%] patients), or in-stent thrombosis (5 [2.3%]
patients).
Perioperative Variables
Both groups had similar crossclamp times, perfusion
times, mean ventilation times, intraoperative blood transfu-
sions, and hospital lengths of stay. There was no significant
difference in the use of arterial grafts between the groups:
95.6% of patients undergoing CABG only and 95.0% of
patients undergoing CABG plus PCI had at least 1 internal
thoracic artery graft (P < .63). The proportion of the
CABG-only group who received more than 1 arterial graft
(free radial artery or a second internal thoracic artery) during
surgical intervention was similar to that in the CABG plus
PCI group (11.6% vs 11.8%, P<.911). Given that patients
undergoing CABG only had more advanced multivessel dis-
ease, the average number of grafts in the CABG group was
higher than in the CABG plus PCI group (3.4 0.9 vs 3.1
1.0, P< .001), but this difference is clinically irrelevant.
Events
Table 2 summarizes unadjusted and adjusted periopera-
tive outcomes. The risk of operative mortality was signifi-
cantly higher in the CABG plus PCI group (adjusted odds
ratio [OR], 4.05; 95% confidence interval [CI],
1.41–11.63). Of 21 operative deaths, 15 (1.0%) occurred
in the CABG-only group, and 6 (2.7%) occurred in the
CABG plus PCI group. Patients undergoing CABG plus
PCI also had a significantly increased risk of perioperative
MACEs (adjusted OR, 2.72; 95% CI, 1.08–6.85). Patients
undergoing CABG plus PCI more frequently had other peri-
operative complications, such as renal failure, new dialysisgery c August 2009
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(n ¼ 221) P value
Preoperative
Age (y) 63.3  9.6 59.7  9.7 .001
Male sex 1137 (74.0) 167 (75.6) .614
BMI 30.1  5.9 31.2  6.3 .013
History of smoking 778 (50.6) 120 (54.3) .306
Hypertension 1188 (77.3) 181 (81.9) .123
History of stroke 118 (7.7) 13 (5.9) .342
History of CHF 247 (16.1) 34 (15.4) .794
Hypercholesterolemia 1187 (77.2) 199 (90.0) .001
Peripheral vascular
disease
203 (13.2) 28 (12.7) .804
History of MI (>24 h) 652 (42.4) 129 (58.4) .001
Diabetic treatment
Missing 2 (0.001) 0 –
Insulin 363 (23.6) 67 (30.3) –
Oral 892 (58.0) 127 (57.5) –
Diet 282 (18.3) 27 (12.2) .089
Medications
Aspirin 933 (60.7) 149 (67.4) .055
ACE inhibitor 581 (38.8) 84 (38.0) .952
b-Blocker 1144 (74.4) 178 (80.5) .048
Lipid-lowering,
nonstatin
28 (1.8) 4 (1.8) .702
Lipid-lowering, statin 421 (27.4) 74 (33.5) .001
STS-predicted risk of
mortality
2.2%  2.2% 1.9%  2.2% .113
Predicted risk of
morbidity/mortality
12.5%  7.5% 12.5%  8.1% .707
Ejection fraction
<40% 252 (16.4) 44 (19.9) –
41%–50% 538 (35.0) 75 (33.9) –
>50% 747 (48.6) 102 (46.2) .423
No. of diseased vessels
1 37 (2.4) 13 (5.9) –
2 191 (12.0) 45 (20.4) –
3 1307 (85.0) 163 (73.8) .001
Left main disease 333 (21.7) 38 (17.2) .127
Time from last PCI to
CABG (mo)




60.8  23.3 59.5  23.7 .476
Perfusion time (min) 90.4  29.2 88.1  30.8 .289
>1 Arterial graft 178 (11.6) 26 (11.8) .911
No. of venous and arterial
grafts
3.4  0.9 3.1  1.0 .001
Intraoperative PRBC
(units)
1.7  1.6 1.3  0.8 .289
Postoperative
Hospital length of stay (d) 7.5  10.8 8.4  14.9 .309
Ventilation time (h) 11.8  38.6 15.2  66.5 .288
Values are presented as the mean  standard deviation and number (percentage) as
shown. CABG, Coronary artery bypass grafting; PCI, percutaneous coronary interven-
tion; SD, standard deviation; BMI, body mass index; CHF, congestive heart failure;
MI, myocardial infarction; ACE, angiotensin-converting enzyme; STS, Society of Tho-
racic Surgeons; PRBC, packed red blood cell.The Journal of Thoracic and Crequirement, prolonged ventilation, and reoperation, but
only the incidence of atrial fibrillation reached statistical
significance (adjusted OR, 1.97; 95% CI, 1.29–3.01).
OE ratios of major perioperative complications were
calculated by using expected incidences of complications
from the national cohort of the STS database. Compared
with the national cohort, patients undergoing CABG plus
PCI experienced more complications than expected because
the OE ratios exceeded 1 for all categories, except for media-
stinitis. OE ratios for patients undergoing CABG plus PCI
exceeded those of patients undergoing CABG only for all
perioperative outcomes except permanent stroke (1.06 vs
1.37) and mediastinitis (0.56 vs 0.66). The greatest disparity
was a difference greater than 2-fold in the OE ratio among
patients undergoing CABG plus PCI for operative mortality
(1.22 vs 0.53).
Major perioperative complications were also stratified
according to the number of diseased vessels. Patients under-
going CABG only with double-vessel disease experienced
significantly more strokes than patients undergoing CABG
plus PCI with double-vessel disease (3.1% vs 2.2%,
P<.045). Furthermore, an analysis of perioperative compli-
cations segregated by the reason for CABG after PCI did not
find any statistical differences.
Multivariable logistic regression revealed significant
independent predictors of operative mortality as follows:
age (OR, 1.11; 95% CI, 1.05–1.18), crossclamp time (OR,
1.034; 95% CI, 1.02–1.05), history of renal failure (OR,
5.44; 95% CI, 1.54–19.23), and history of PCI (OR, 4.05;
95% CI, 1.41–11.63).
Intermediate-Term Survival
An age-adjusted hazard plot for all-cause mortality is
shown in Figure 2. The median follow-up time was 3.6 
2.0 years (CABG only, 3.6 years; CABG plus PCI, 3.4
years). At 2 years’ follow-up, there were a total of 94 deaths:
78 deaths occurred in the CABG-only group, and 16 deaths
occurred in the CABG plus PCI group. The age-adjusted
survival of the CABG-only group was significantly better
compared with that seen in the CABG plus PCI group
(93.4% vs 87.4%, P< .017).
Table 3 presents hazard ratios for all-cause mortality at 2
years’ follow-up. Although low EF (<40%) increased the
risk of mortality for all patients, this was significant only
in the CABG-only group (hazard ratio, 1.91; 95% CI,
1.29–2.84). Hazard ratios for all-cause mortality at 2 years
were not statistically different when analyzed by number
of stents placed or number of diseased vessels.
Multivariable logistic regression for death at 2 years’
follow-up identified the following variables as independent
predictors of mortality: age (OR, 1.10; 95% CI, 1.06–1.13),
reduced EF (OR, 1.03; 95%CI, 1.01–1.05), peripheral vascu-
lar disease (OR, 3.30; 95% CI, 1.97–5.54), and preoperative
creatinine value (OR, 1.20; 95% CI, 1.01–1.43). A history ofardiovascular Surgery c Volume 138, Number 2 319
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DTABLE 2. Frequency of perioperative complications by group
CABG (n ¼ 1537) CABGþPCI (n ¼ 221) Unadjusted OR ± 95% CI Adjusted OR ± 95% CI*
MACEs 19 (1.2) 8 (3.6) 2.47 (1.09–5.60) 2.72 (1.08-6.85)
Permanent stroke 25 (1.6) 3 (1.4) 0.83 (0.25–2.78) 1.212 (0.35–4.18)
Transient stroke 14 (0.9) 2 (0.9) 0.99 (0.22–4.40) 1.12 (0.24–5.38)
Continuous coma 5 (0.3) 0 (0.0) – –
Prolonged ventilation time 74 (4.8) 11 (5.0) 1.05 (0.54–1.98) 1.14 (0.56–2.28)
Tamponade 10 (0.7) 1 (0.5) 0.69 (0.09–5.45) 0.52 (0.06–4.40)
Atrial fibrillation 172 (11.2) 36 (16.3) 1.54 (1.05–2.28) 1.97 (1.29–3.01)
Reoperation for bleeding 22 (1.4) 3 (1.4) 0.95 (0.28–3.19) 0.98 (0.29–3.34)
Renal failure 57 (3.7) 9 (4.1) 1.10 (0.53–2.26) 1.06 (0.49–2.30)
Renal failure/dialysis required 17 (1.1) 5 (2.3) 2.07 (0.76–5.68) 1.80 (0.57–5.70)
Operative death 15 (1.0) 6 (2.7) 2.65 (1.03–6.85) 4.05 (1.41–11.63)
*Adjusted for age, sex, body mass index, hypertension, smoking, congestive heart failure, left ventricular ejection fraction, New York Heart Association functional class, family
history of coronary artery disease, preoperative platelet use, arrhythmia, cerebrovascular accident, peripheral vascular disease, chronic obstructive pulmonary disease, history of
renal failure, and crossclamp time. CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention; OR, odds ratio; CI, confidence interval.PCI (OR, 1.76; 95% CI, 0.92–3.39) predicted mortality but
with a CI that suggested no statistical significance.
DISCUSSION
We observed that diabetic patients with a history of PCI
with stenting before CABG had a significantly higher
adjusted risk of operative mortality and worse age-adjusted
survival at 2 years’ follow-up compared with that seen in
similar patients without a history of PCI. The operative
mortality for the CABG-only group was low (1.0%) and
similar to mortality rates reported by other clinical registries,
such as the New York State, Northern New England, and
Texas State databases.4,6,14 We also found that the risk of
MACEs was significantly increased in patients undergoing
CABG plus PCI.
To our knowledge, this is the first observational study to
report on the effect of a history of prior PCI on both early
and intermediate–term outcomes in diabetic patients under-
going subsequent CABG. Although an EF of less than 40%
was associated with worsened survival in the CABG-only
group, we did not observe that preoperative factors, such
as the number of stents, left main disease, indication for sur-
FIGURE 2. Hazard plot adjusted for age: comparison between patients
undergoing coronary artery bypass grafting (CABG) only and patients
undergoing coronary artery bypass grafting plus percutaneous coronary
intervention (PCI).320 The Journal of Thoracic and Cardiovascular Sugical intervention after PCI, or severity of coronary disease,
were prognostic of intermediate-term outcome. However,
multivariate analysis demonstrated that age, reduced EF,
peripheral vascular disease, and increased preoperative
creatinine value independently predicted death at 2 years’
follow-up. A history of prior PCI was also recognized as
a predictor of death at 2 years’ follow-up, but the CIs did
not achieve statistical significance and might be related to
lack of power.
Possibly because of the clinical equipoise regarding the
survival benefits of CABG compared with PCI, considerable
practice variation exists in determining which strategy to ini-
tially use for revascularization. Data from multiple clinical
registries have reported superior survival and decreased
need for repeat revascularization with CABG compared
with PCI in patients with multivessel disease.4-6 However,
some results from randomized trials in the stent era have







CABGþPCI 1.49 (0.86–2.61) – –
EF (%) 0.97 (0.96–0.99) 0.97 (0.95–0.99) 0.98 (0.94–1.02)
EF<40% 2.49 (0.47–4.21) 2.77 (1.57–4.88) 1.31 (0.31–5.46)
EF 41% to 50% 1.43 (0.87–2.37) 1.34 (0.77–2.35) 1.82 (0.57–5.72)
EF>50% – – –
Left main disease 1.06 (0.64–1.76) 1.05 (0.60–1.82) 1.24 (0.35–4.40)
Triple-vessel
disease
0.52 (0.21–1.29) 0.45 (0.17–1.25) 1.02 (0.13–7.86)
Double-vessel
disease






>1 vs 1 – – 0.43 (0.15–1.25)
>2 vs 2 – – 0.26 (0.03–1.97)
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention; EF,
ejection fraction.rgery c August 2009
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Dbeen discordant.1,2 The Bypass Angioplasty Revasculariza-
tion Investigation trial observed a significant survival
advantage with CABG over angioplasty in diabetic patients,
whereas the Arterial Revascularization Therapies Study trial
found no difference between surgical intervention and stent-
ing.3,15 Regardless, data from trial and registry data have
consistently shown that nondiabetic and diabetic patients
treated with primary CABG have decreased necessity for
reintervention compared with patients treated with PCI.
The necessity of repeat revascularization is magnified in
diabetic patients because they have more adverse outcomes
after PCI. Although procedural success with PCI in diabetic
patients is equivalent to that seen in nondiabetic patients, the
rate of symptom recurrence and restenosis after stent deploy-
ment is significantly increased in diabetic patients.16,17
Drug-eluting stents significantly reduce restenosis; however,
even recent registry data have continued to report improved
outcomes with CABG over drug-eluting stents in terms of
lower mortality, MI, and repeat revascularization.18,19
Thus despite the attempts to defer CABG by pursuing stent-
ing initially in patients with multivessel disease, CABG is
merely delayed at substantial expense and higher cumulative
procedural morbidity, mortality, or both.
Our findings are consistent with other reports in the liter-
ature that have been previously focused on in-hospital
outcomes. Thielmann and colleagues20 examined patients
undergoing first-time elective CABG and concluded that
a history of prior PCI was an independent risk factor for
significantly increased in-hospital mortality and MACEs.
This conclusion was recently confirmed in a large multicen-
ter study.21 In a subset of diabetic patients with triple-vessel
disease, these authors found a similarly increased risk of
in-hospital mortality.12 In a large cohort of 6032 patients,
Hassan and associates22 observed that patients with prior
PCI had greater in-hospital morality after CABG, despite
having less coronary disease and comorbidities. One micro-
simulation study, using previously published data, estimated
that prior coronary stenting worsened 10-year survival of
patients undergoing CABG by 3.3%.23 A reanalysis of
data from the Ischemia Management with Accupril Post
Bypass Graft via Inhibition of the Converting Enzyme study
demonstrated that patients with prior PCI hadworse outcome
after CABG, as manifested by increased hospitalization for
unstable angina and need for coronary revascularization.24
These previous studies could not completely elucidate why
patients with previous PCI carry an increased operative risk,
and unfortunately, our study is similarly limited in that re-
spect. However, there are several mechanisms worthwhile
of consideration that might help to explain the cause behind
this increased risk. Patients who require a repeat revasculari-
zation procedure with CABG after PCI might have a more
progressive form of atherosclerosis, perhaps promoting
more numerous coronary lesions or a higher rate of restenosis.
In this study patients undergoingCABGplus PCI had a higherThe Journal of Thoracic and Cincidence of hypercholesterolemia and MI; the majority of
these patients underwent surgical intervention because of pro-
gression of de novo coronary artery disease presumably
refractory to appropriate medical management after stenting.
Prior PCI might not only be a proxy marker of more
advanced or aggressive disease, but the presence of a stent
might itself induce deleterious mechanisms inside the coro-
nary artery. Stenting can inhibit protective collateralization,
resulting in more acute presentation of disease. It has been
shown to induce periprocedural myocardial injury, which
initiates a secondary inflammatory cascade, formation of
platelet microaggregates, and microvascular plugging from
plaque debris and microemboli.25,26 The presence of a previ-
ous stent might force graft anastomoses to be inserted more
distally into target vessels with smaller diameters, thereby
compromising runoff and patency rates. Moreover, there is
emerging evidence that the use of newer drug-eluting stents,
especially in off-label situations, might reduce restenosis at
the high cost of late in-stent thrombosis with associated
high mortality.27 This risk has been found to be higher in
diabetic patients and persists with time.28 These patients
might be especially vulnerable to in-stent thrombosis while
not taking antiplatelet agents, such as during the periopera-
tive period.29
The burgeoning recognition in the literature of the effects
of prior PCI on CABG outcomes has yet to translate into
changes of clinical practice and management. Current risk
models to assess the risk of operativemortality andmorbidity
after CABG do not adequately prognosticate the additional
risk conferred by a history of prior PCI. For instance, neither
the logistic or additive EuroSCORE calculators include a his-
tory of prior PCI as a risk factor. Although the STS CABG
risk model does use a history of prior PCI as a risk factor, it
is only weighted in risk calculations if PCI occurred within
6 hours of CABG. Perhaps what might be required is to
re-examine the cohorts from which these models are derived
to accurately determine themagnitude of the increased risk of
prior PCI. In the interim, patients who present for CABG
after previous PCI should at the very least be followed with
increased attention and surveillance to mitigate perioperative
and long-term complications.
Limitations
Several limitations exist with this study. This was
a nonrandomized retrospective study at a single center,
which might limit the ability to generalize these results to
other institutions. However, a strength of this study is that
the data were gathered prospectively by using standardized
definitions, which minimizes selection and recall bias.
Although the 2 groups in this study were not randomized,
the STS-predicted risk of mortality was similar for both
groups in this study, which suggests the differences in base-
line risk factors were minimally significant. We could not
control for differences in management preoperatively orardiovascular Surgery c Volume 138, Number 2 321
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Dafter discharge, such as statin use. Despite a high prevalence
of hypercholesterolemia, only a minority of patients in both
groups were treated with statins at the time of surgical inter-
vention, and significantly more patients in the CABG plus
PCI group received statins. Several contemporary studies
observed similarly low rates of statin therapy (35.9% to
46%) in patients with coronary artery disease and
CABG.30,31 It is likely that more prevalent preoperative sta-
tin use, especially in the CABG plus PCI group, could have
led to reduced need for surgical revascularization and perio-
perative MACEs.32
Because of limited cardiac catheterization data, the type of
stent (bare metal or drug eluting) was unable to be ascer-
tained in many cases. Therefore we could not comment on
whether there were any associated differences in outcome
based on the type of stent used. In approximately 4% of
patients, the location of previous stents was unknown as
well; thus in some instances it was unknown whether
a bypass graft was placed in a stented vessel.
Lastly, clinical data on patients after discharge were
limited and inconsistent. We were unable to quantify the
need for repeat revascularization or the incidence of graft
failure. Although we were able to obtain mortality data after
discharge, for approximately 30% of the patients in each
group, the cause of death was not reported. Thus we could
not specifically relate the difference in survival between
the groups to cardiac or noncardiac factors.
CONCLUSION
The findings of this study highlight the significantly
increased perioperative and intermediate-term risk of dia-
betic patients who had PCI before CABG. With improved
decision making and patient selection, hopefully clinical
outcomes will improve by selecting the most appropriate
method of initial revascularization to reduce the need for
patients to have repeat revascularizations. This might best
be accomplished by a multidisciplinary team involving at
least a cardiologist and cardiac surgeon, who cooperatively
can analyze and discuss not only the immediate risks and
benefits of revascularization but also the future hazards
should a repeat procedure be required.
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